NCT05218850 The Use of Butyrate Therapy in Pediatric Ulcerative Colitis
| NCT ID | NCT05218850 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Children's Hospital Los Angeles |
| Condition | Ulcerative Colitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2022-06-29 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 10 participants in total. It began in 2022-06-29 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Butyrate is an important metabolite produced by the gut microbiome and has been shown as a helpful therapy in ulcerative colitis. This is a feasibility study to determine the efficacy of butryate enemas in pediatric ulcerative colitis.
Eligibility Criteria
Inclusion Criteria: * 7-21 years, mild to moderate ulcerative colitis Exclusion Criteria: * UC therapy within 4 weeks of study medication initiation * infectious colitis, -pregnancy
Contact & Investigator
Sonia Michail, MD
PRINCIPAL INVESTIGATOR
Children's Hospital Los Angeles
Frequently Asked Questions
Who can join the NCT05218850 clinical trial?
This trial is open to participants of all sexes, aged 7 Years or older, up to 21 Years, studying Ulcerative Colitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05218850 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT05218850 currently recruiting?
Yes, NCT05218850 is actively recruiting participants. Contact the research team at sonia.michail@hotmail.com for enrollment information.
Where is the NCT05218850 trial being conducted?
This trial is being conducted at Los Angeles, United States.
Who is sponsoring the NCT05218850 clinical trial?
NCT05218850 is sponsored by Children's Hospital Los Angeles. The principal investigator is Sonia Michail, MD at Children's Hospital Los Angeles. The trial plans to enroll 10 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.